Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 7/20 | 0.58 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309229 | 0.98 | GHSR (0.60) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29748708 | 0.94 | GHSR (0.61) | GHSR | |
| SCHEMBL29619338 | 0.93 | GHSR (0.60) | GHSR | |
| SCHEMBL30414279 | 0.93 | OPRM1 (0.58) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL30797170 | 0.93 | OPRM1 (0.57) | OPRM1OPRD1ERAP2ERAP1LNPEP | |
| SCHEMBL29972999 | 0.92 | GHSR (0.62) | GHSR | |
| SCHEMBL30485843 | 0.92 | GHSR (0.57) | GHSRNPY1RNPY2RNPY4RC5AR1 | |
| SCHEMBL29808394 | 0.91 | GHSR (0.63) | GHSR | |
| SCHEMBL29666286 | 0.91 | GHSR (0.59) | GHSR | |
| SCHEMBL30751948 | 0.91 | GHSR (0.56) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12297502-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-04-03 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2023-06-29 | — | — | US | disclosed |
| US-11628198-B2 | Methods for prevention and treatment of acute renal injury | CORNELL UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | CORNELL UNIVERSITY (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230033758-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-11534476-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11447523-B2 | Methods for reducing CD36 expression | CORNELL RESEARCH FOUNDATION, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11312993-B2 | Methods and compositions for detecting and diagnosing diseases and conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11266709-B2 | Methods for the regulation of matrix metalloproteinase expression | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | HSPA9, OPA1, ARG2 | GHSR 3737/4885NPY1R 3418/4885NPY2R 3332/4885 |
| US-20240024408-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | CLN6, PRPH, TSG101 | GHSR 3129/4885NPY1R 2329/4885NPY2R 1926/4885 |
| US-11628198-B2 | Methods for prevention and treatment of acute renal injury | ARG2, SERPINC1, ARG1 | GHSR 1450/4885NPY1R 412/4885NPY2R 431/4885 |
| US-11534476-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | GHSR 918/4885NPY1R 807/4885NPY2R 696/4885 |
| US-20250109167-A1 | METHODS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE | NLN, OAT, HAGH | GHSR 3379/4885NPY1R 649/4885NPY2R 704/4885 |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | MUSK, TNNC1, TNNI3 | GHSR 469/4885NPY1R 322/4885NPY2R 476/4885 |
| US-20240100119-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF FRIEDREICH'S ATAXIA | OAT, TFAM, OTC | GHSR 3931/4885NPY1R 1085/4885NPY2R 1068/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | GHSR 4526/4885NPY1R 3326/4885NPY2R 3526/4885 |
| US-20220280593-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | GHSR 1781/4885NPY1R 209/4885NPY2R 317/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | GHSR 2407/4885NPY1R 1155/4885NPY2R 1797/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | GHSR 947/4885NPY1R 534/4885NPY2R 576/4885 |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | GHSR 1557/4885NPY1R 913/4885NPY2R 313/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | GHSR 4658/4885NPY1R 3368/4885NPY2R 4078/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | GHSR 1781/4885NPY1R 209/4885NPY2R 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.